Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis

Table 4

Comparisons of frequencies of ExRA and specific extra-articular manifestations according to the findings of positive or negative anti-CCP or anti-MCV.

Characteristics	(−) RF; 𝑛=69	(+) RF; 𝑛=135	𝑃	(−) anti-CCP; 𝑛=70	(+) anti-CCP; 𝑛=155	𝑃	(−) anti-MCV; 𝑛=68	(+) anti-MCV; 𝑛=157	𝑃
Presence of ExRA, 𝑛 (%)	30 (43.5)	57 (42.2)	0.86	27 (38.6)	68 (43.9)	0.46	26 (38.2)	69 (43.9)	0.43
Specific manifestations
Sjögren syndrome, 𝑛 (%)	23 (33.3)	29 (21.5)	0.07	18 (25.7)	40 (25.8)	1.00	16 (23.5)	42 (26.8)	0.61
Chronic anemia, 𝑛 (%)	9 (13.0)	23 (17.0)	0.46	7 (10.0)	26 (16.8)	0.18	9 (13.2)	24 (15.3)	0.69
Rheumatoid nodules, 𝑛 (%)	2 (2.9)	19 (14.1)	0.01	3 (4.3)	20 (12.9)	0.048	2 (2.9)	21 (13.4)	0.02
P. neuropathy, 𝑛 (%)	6 (8.7)	5 (3.7)	0.19	5 (7.1)	7 (4.5)	0.52	4 (5.9)	8 (5.1)	0.76

The cut-off value to be considered anti-CCP as positive was ≥5 IU/mL, for anti-MCV, the levels considered as positive were ≥20 IU/mL. RA: rheumatoid arthritis; ExRA: extra-articular manifestations; anti-CCP: anti-cyclic citrullinated peptide antibodies; anti-MCV: anti-mutated citrullinated vimentin antibodies, P. neuropathy (peripheral neuropathy). Qualitative variables are expressed as frequencies (%). Comparisons between proportions were compared with Fisher exact test.